EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma

April 5, 2018 – On April 3, the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC who are not candidates for surgery. Cemiplimab is an investigational human monoclonal antibody targeting the checkpoint inhibitor programmed cell death protein 1 (PD-1). The MAA for … (leggi tutto)